Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Recurrence × Sorafenib × Clear all

Phase

Status

Completed 8 Withdrawn 1 Terminated 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 6 Leukemia, Myeloid, Acute 5 Thyroid Neoplasms 2 Neoplasms 2 Neoplasm Metastasis 2 Hepatoblastoma 2 Thyroid cancer, Hurthle cell 1 Thyroid Diseases 1 Squamous Cell Carcinoma of Head and Neck 1 Sarcoma, Myeloid 1 Rhabdomyosarcoma 1 Recurrence 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pancreatic Neoplasms 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neuroblastoma 1 Myelodysplastic Syndromes 1 Melanoma 1 Gastrointestinal Stromal Tumors 1 Fibrolamellar hepatocellular carcinoma 1 Desmoplastic Small Round Cell Tumor 1 Carcinoma 1

Interventions

Cyclophosphamide 18 Dexamethasone 17 fludarabine 11 pomalidomide 8 carfilzomib 7 Rituximab 7 pembrolizumab 6 fludarabine phosphate 6 daratumumab 6 Lenalidomide 6 Calcium Dobesilate 6 venetoclax 5 Gemcitabine 5 Cisplatin 5 Bortezomib 5 Nivolumab 4 Etoposide 4 isatuximab 3 elotuzumab 3 Vincristine 3 Prednisone 3 Ipilimumab 3 Injections 3 Doxorubicin 3 Carboplatin 3 tisagenlecleucel 2 ruxolitinib 2 obinutuzumab 2 dexamethasone 21-phosphate 2 cemiplimab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02298348 2025-02-17

N2013-02

New Approaches to Neuroblastoma Therapy Consortium

Phase 1 Active not recruiting

Neuroblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡